TMEM30A loss-of-function mutations drive lymphomagenesis and confer therapeutically exploitable vulnerability in B-cell lymphoma-Reference-Cited by-同舟云学术

TMEM30A loss-of-function mutations drive lymphomagenesis and confer therapeutically exploitable vulnerability in B-cell lymphoma

Published:2020-02-24 Issue:4 Volume:26 Page:577-588
ISSN:1078-8956
Container-title:Nature Medicine
language:en
Short-container-title:Nat Med

Author:

Ennishi Daisuke,Healy Shannon,Bashashati Ali,Saberi Saeed,Hother Christoffer^ORCID,Mottok Anja^ORCID,Chan Fong Chun,Chong Lauren,Abraham Libin,Kridel Robert^ORCID,Boyle Merrill,Meissner Barbara,Aoki Tomohiro^ORCID,Takata Katsuyoshi,Woolcock Bruce W.,Viganò Elena,Gold Michael^ORCID,Molday Laurie L.,Molday Robert S.^ORCID,Telenius Adele^ORCID,Li Michael Y.,Wretham Nicole^ORCID,Dos Santos Nancy,Wong Mark,Viller Natasja N.,Uger Robert A.,Duns Gerben,Baticados Abigail^ORCID,Madero Angel,Bristow Brianna N.,Farinha Pedro^ORCID,Slack Graham W.,Ben-Neriah Susana,Lai Daniel^ORCID,Zhang Allen W.^ORCID,Salehi Sohrab,Shulha Hennady P.,Chiu Derek S.,Mostafavi Sara,Gerrie Alina S.,Huang Da Wei,Rushton Christopher,Villa Diego^ORCID,Sehn Laurie H.,Savage Kerry J.,Mungall Andrew J.^ORCID,Weng Andrew P.,Bally Marcel B.,Morin Ryan D.^ORCID,Cohen Freue Gabriela V.,Staudt Louis M.,Connors Joseph M.,Marra Marco A.^ORCID,Shah Sohrab P.,Gascoyne Randy D.,Scott David W.,Steidl Christian^ORCID

Funder

Terry Fox Research Institute

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

http://www.nature.com/articles/s41591-020-0757-z.pdf

Reference49 articles.

1. Swerdlow, S. H. et al. The 2016 revision of the World Health Organization (WHO) classification of lymphoid neoplasms. Blood 127, 2375–2390 (2016).

2. Coiffier, B. et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med. 346, 235–242 (2002).

3. Sehn, L. H. et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J. Clin. Oncol. 23, 5027–5033 (2005).